Earnings ·
Sanofi reports Q3 sales up 14.3% at CER and upgrades FY26 guidance
SNYNFSanofi
Sanofi reported third-quarter net sales of €14,444 million, a 14.3% increase at constant exchange rates (CER), driven by double-digit growth in pharma launches and Dupixent sales reaching €5.7 billion. Business earnings per share rose 19.6% to €3.55 at CER, supported by cost discipline and operating leverage. The company upgraded its full-year 2026 guidance, now expecting low-teens sales growth and mid-teens business EPS growth at CER. Additionally, Sanofi announced an expanded collaboration with Regeneron involving a $1 billion upfront payment for new immunology assets and a strategic partnership with Cheplapharm to divest mature medicines. The company operates in the pharmaceutical industry, developing and marketing prescription drugs, vaccines, and consumer health products.